The Motley Fool
19 Nov 2026, 20:45 UTC · 26m ago
3 Dividend Kings to Buy in November and Never Sell
Impact · against what's priced in
The article provides no new catalysts for Abbott or McDonald's, as the market has already priced in Abbott's nutrition spin-off and McDonald's turnaround efforts. Tennant is the only potential outlier, though the specific 'catalyst' for recovery is not detailed in the text.
- ABT+0.00
Already priced in
- The price assumes
A re-rating of the diagnostics segment back to growth, worth up to 16% if the decline reverses.
The article's claim that spinning off the nutrition division could lead to a re-rating is already reflected in the market's current view of segment stabilization and potential recovery.
What ABT's price assumes · Sep 12





